Following a consultation with the US Food and Drug Administration (FDA), and in accordance with the requirements of the FDA’s Accelerated Approval Program, Genentech has chosen to withdraw the US indication of atezolizumab for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC bladder cancer) who are not eligible for cisplatin-containing chemotherapy, and whose tumours express PD-L1 or who are not eligible for any platinum-containing chemotherapy, regardless of PD-L1 status.
